| The novel pan-PIM kinase inhibitor, PIM447, displays dual antimyeloma and bone-protective effects, and potently synergizes with current standards of care T Paino, A Garcia-Gomez, L González-Méndez, L San-Segundo, ... Clinical Cancer Research 23 (1), 225-238, 2017 | 60 | 2017 |
| Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma EM Algarín, A Díaz-Tejedor, P Mogollón, S Hernández-García, ... Haematologica 105 (3), e116, 2020 | 50 | 2020 |
| Biological background of resistance to current standards of care in multiple myeloma P Mogollón, A Díaz-Tejedor, EM Algarín, T Paíno, M Garayoa, EM Ocio Cells 8 (11), 1432, 2019 | 30 | 2019 |
| Filanesib for the treatment of multiple myeloma EM Algarín, S Hernández-García, M Garayoa, EM Ocio Expert opinion on investigational drugs 29 (1), 5-14, 2020 | 27 | 2020 |
| The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma S Hernández-García, L San-Segundo, L González-Méndez, LA Corchete, ... Haematologica 102 (12), 2113, 2017 | 26 | 2017 |
| Protein translation inhibition is involved in the activity of the pan-PIM kinase inhibitor PIM447 in combination with pomalidomide-dexamethasone in multiple myeloma T Paíno, L González-Méndez, L San-Segundo, LA Corchete, ... Cancers 12 (10), 2743, 2020 | 12 | 2020 |
| Stroma-mediated resistance to S63845 and venetoclax through MCL-1 and BCL-2 expression changes induced by miR-193b-3p and miR-21-5p dysregulation in multiple myeloma EM Algarín, D Quwaider, FJ Campos-Laborie, A Díaz-Tejedor, ... Cells 10 (3), 559, 2021 | 4 | 2021 |
| The hybrid molecule, Edo-S101, impairs double strand breaks repair in multiple myeloma and synergizes with bortezomib and dexamethasone AA López-Iglesias, AB Herrero, L San-Segundo, S Hernández-García, ... Blood 126 (23), 5354, 2015 | 2 | 2015 |
| Filanesib primarily initiates the apoptotic program by activating Bax through a calpain-dependent mechanism S Hernández-García, L González-Méndez, I Misiewicz-Krzeminska, ... Blood 126 (23), 5353, 2015 | 2 | 2015 |
| Mechanisms underlying the synergistic interaction of filanesib with pomalidomide and dexamethasone (FPD) in multiple myeloma S Hernández-García, L San-Segundo, L González-Méndez, ... Blood 126 (23), 1801, 2015 | 1 | 2015 |
| Prognostic implications of PIM-2 expression in samples from patients with chronic lymphocytic leukemia and impact in the sensitivity to the pan-PIM kinase inhibitor PIM447 AA López-Iglesias, I Misiewicz-Krzeminska, I Criado, M Alcoceba, ... Blood 126 (23), 2923, 2015 | 1 | 2015 |
| The novel pan-PIM kinase inhibitor, LGH447, shows dual antitumoral and bone antiresorptive effect in multiple myeloma and synergizes with standard-of-care treatments T Paíno, A García-Gómez, L González-Méndez, L San-Segundo, ... Clinical Lymphoma Myeloma and Leukemia 15, e222, 2015 | 1 | 2015 |
| Mechanisms Regulating Myeloma Cell Responsiveness to Antisense Oligonucleotides Targeting IRF4 R Shirasaki, EM Algarin, RDM Simoes, SL Downey-Kopyscinski, ... Blood 136, 32, 2020 | | 2020 |
| Resumen de tesis. Preclinical evaluation of BH3-mimetics targeting MCL-1 (S63845) and BCL-2 (venetoclax) in multiple myeloma EM Algarín | | 2020 |
| Antimyeloma Effect of the Simultaneous Inhibition of MCL-1 (with S63845) and BCL-2 (with Venetoclax) in the Presence of the Microenvironment EM Algarín, A Díaz-Tejedor, P Mogollón, S Hernández-García, L Corchete, ... Blood 132, 954, 2018 | | 2018 |
| MECHANISMS RESPONSIBLE FOR THE DE-REGULATION OF CEREBLON AS A CENTRAL ELEMENT IN RESISTANCE TO IMMUNOMODULATORS IN MULTIPLE MYELOMA P Mogollon, L Gonzalez-Mendez, S Hernandez-Garcia, P Krzeminski, ... HAEMATOLOGICA 103, 84-85, 2018 | | 2018 |
| DEVELOPMENT OF A MODEL OF RESISTANCE TO CYTOTOXICITY DEPENDENT COMPLEMENTS MEDIATED BY ANTI-CD38 MONOCLONAL ANTIBODIES IN MULTIPLE MYELOMA A Diaz-Tejedor, L Gonzalez-Mendez, EM Algarin, M Martin-Sanchez, ... HAEMATOLOGICA 103, 85-85, 2018 | | 2018 |
| CIRCULATING MICROVESCULARS OF PATIENTS WITH MULTIPLE MYELOMA INHIBIT THE CITOTOXIC FUNCTION OF NATURAL KILLER CELLS EM Algarin, T Paino, P Anton, A Diaz Tejedor, L Corchete, ... HAEMATOLOGICA 102, 9-10, 2017 | | 2017 |
| EVALUATION OF THE VIA OF MAPK AS A POTENTIAL MECHANISM OF RESISTANCE TO IMMUNOMODULATOR DRUGS (IMIDS) plus DEXAMETASONE IN MULTIPLE MYELOMA (MM) P Mogollon, L Gonzalez Mendez, L San Segundo, EM Algarin, ... HAEMATOLOGICA 102, 12-12, 2017 | | 2017 |
| THE PAN-INHIBITOR OF PIM KINASES, PIM447, POWER THE EFFECT OF POMALIDOMIDE AND DEXAMETASONE IN MULTIPLE MYELOMA T Paino, L San Segundo, S Hernandez Garcia, L Gonzalez Mendez, ... HAEMATOLOGICA 102, 3-4, 2017 | | 2017 |
